{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:17:59Z","timestamp":1776287879988,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metaiodobenzylguanidine (MIBG) labeled with radioisotopes can be used for diagnostics <jats:sup>123<\/jats:sup>I<jats:sup>\u2212<\/jats:sup>) and treatment (<jats:sup>131<\/jats:sup>I<jats:sup>\u2212<\/jats:sup>) in patients with neuroblastic tumors. Thyroid dysfunction has been reported in 52% of neuroblastoma (NBL) survivors after <jats:sup>131<\/jats:sup>I-MIBG, despite thyroid protection. Diagnostic <jats:sup>123<\/jats:sup>I-MIBG is not considered to be hazardous for thyroid function; however, this has never been investigated. Therefore, the aim of this study was to evaluate the prevalence of thyroid dysfunction in survivors of a neuroblastic tumor who received diagnostic <jats:sup>123<\/jats:sup>I-MIBG only.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thyroid function and uptake of <jats:sup>123<\/jats:sup>I<jats:sup>\u2212<\/jats:sup> in the thyroid gland after <jats:sup>123<\/jats:sup>I-MIBG administrations were evaluated in 48 neuroblastic tumor survivors who had not been treated with <jats:sup>131<\/jats:sup>I-MIBG. All patients had received thyroid prophylaxis consisting of potassium iodide or a combination of potassium iodide, thiamazole and thyroxine during exposure to <jats:sup>123<\/jats:sup>I-MIBG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After a median follow-up of 6.6\u00a0years, thyroid function was normal in 46 of 48 survivors (95.8%). Two survivors [prevalence 4.2% (95% CI 1.2\u201314.0)] had mild thyroid dysfunction. In 29.2% of the patients and 11.1% of images <jats:sup>123<\/jats:sup>I<jats:sup>\u2212<\/jats:sup> uptake was visible in the thyroid. In 1 patient with thyroid dysfunction, weak uptake of <jats:sup>123<\/jats:sup>I<jats:sup>\u2212<\/jats:sup> was seen on 1 of 10 images.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of thyroid dysfunction does not seem to be increased in patients with neuroblastic tumors who received <jats:sup>123<\/jats:sup>I-MIBG combined with thyroid protection. Randomized controlled trials are required to investigate whether administration of <jats:sup>123<\/jats:sup>I-MIBG without thyroid protection is harmful to the thyroid gland.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-022-01743-7","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T09:02:36Z","timestamp":1651482156000},"page":"579-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors"],"prefix":"10.1007","volume":"36","author":[{"given":"Sarah C.","family":"Clement","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godelieve A. M.","family":"Tytgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S. Paul","family":"van Trotsenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leontien C. M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke M.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"1743_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ejca.2013.11.016","volume":"50","author":"JS Wilson","year":"2014","unstructured":"Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50:801\u201315.","journal-title":"Eur J Cancer"},{"key":"1743_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1148\/rg.2016150099","volume":"36","author":"SE Sharp","year":"2016","unstructured":"Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258\u201378.","journal-title":"Radiographics"},{"key":"1743_CR3","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/pbc.24681","volume":"60","author":"SC Clement","year":"2013","unstructured":"Clement SC, van Eck-Smit BLF, van Trotsenburg ASP, et al. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance. Pediatr Blood Cancer. 2013;60:1833\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"1743_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00259-014-2967-4","volume":"42","author":"SC Clement","year":"2015","unstructured":"Clement SC, van Rijn RR, van Eck-Smit BLF, et al. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Eur J Nucl Med Mol Imaging. 2015;42:706\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1743_CR5","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/cncr.10447","volume":"94","author":"HM van Santen","year":"2002","unstructured":"van Santen HM, de Kraker J, van Eck BLF, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during 131I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002;94:2081\u20139.","journal-title":"Cancer"},{"key":"1743_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cncr.11523","volume":"98","author":"HM van Santen","year":"2003","unstructured":"van Santen HM, de Kraker J, van Eck BLF, et al. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer. 2003;98:389\u201396.","journal-title":"Cancer"},{"key":"1743_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/pbc.22767","volume":"56","author":"A Quach","year":"2011","unstructured":"Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56:191\u2013201.","journal-title":"Pediatr Blood Cancer"},{"key":"1743_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.647361","volume":"11","author":"M Ussowicz","year":"2021","unstructured":"Ussowicz M, Wieczorek A, D\u0142u\u017cniewska A, et al. Factors modifying outcome after MIBG therapy in children with neuroblastoma\u2014a national retrospective study. Front Oncol. 2021;11: 647361.","journal-title":"Front Oncol"},{"key":"1743_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-010-1545-7","volume":"37","author":"E Bombardieri","year":"2010","unstructured":"Bombardieri E, Giammarile F, Aktolun C, et al. 131I\/123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436-46.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1743_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/jc.2013-1891","volume":"99","author":"J L\u00e9ger","year":"2014","unstructured":"L\u00e9ger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab. 2014;99:363\u201384.","journal-title":"J Clin Endocrinol Metab"},{"key":"1743_CR11","first-page":"1049","volume":"27","author":"G Catli","year":"2014","unstructured":"Catli G, Abaci A, B\u00fcy\u00fckgebiz A, et al. Subclinical hypothyroidism in childhood and adolescense. J Pediatr Endocrinol Metab. 2014;27:1049\u201357.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1743_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0300-2977(94)00089-R","volume":"46","author":"W Wiersinga","year":"1995","unstructured":"Wiersinga W. Subclinical hypothyroidism and hyperthyroidism. I. Prevalence and clinical relevance. Neth J Med. 1995;46:197\u2013204.","journal-title":"Neth J Med"},{"key":"1743_CR13","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1210\/jc.2015-1690","volume":"100","author":"F de Vathaire","year":"2015","unstructured":"de Vathaire F, Haddy N, Allodji RS, et al. Thyroid radiation dose and other risk factors of thyroid carcinoma following childhood cancer. J Clin Endocrinol Metab. 2015;100:4282\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"1743_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1667\/RR2240.1","volume":"174","author":"P Bhatti","year":"2010","unstructured":"Bhatti P, Veiga LHS, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741\u201352.","journal-title":"Radiat Res"},{"key":"1743_CR15","first-page":"459","volume":"56","author":"A Piccardo","year":"2012","unstructured":"Piccardo A, Foppiani L, Puntoni M, et al. Role of low-cost thyroid follow-up in children treated with radiotherapy for primary tumors at high risk of developing a second thyroid tumor. Q J Nucl Med Mol Imaging. 2012;56:459\u201367.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1743_CR16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1038\/s41409-021-01258-1","volume":"56","author":"S Haghiri","year":"2021","unstructured":"Haghiri S, Fayech C, Mansouri I, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant. 2021;56:1984\u201397.","journal-title":"Bone Marrow Transplant"},{"key":"1743_CR17","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/S0140-6736(05)66695-0","volume":"365","author":"AJ Sigurdson","year":"2005","unstructured":"Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365:2014\u201323.","journal-title":"Lancet"},{"key":"1743_CR18","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1210\/jc.2003-030209","volume":"88","author":"HM van Santen","year":"2003","unstructured":"van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab. 2003;88:3657\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1743_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1158\/1055-9965.EPI-11-0576","volume":"21","author":"LHS Veiga","year":"2012","unstructured":"Veiga LHS, Bhatti P, Ronckers CM, et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol Biomark Prev. 2012;21:92\u2013101.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1743_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2967\/jnumed.113.124826","volume":"55","author":"NC Friedman","year":"2014","unstructured":"Friedman NC, Hassan A, Grady E, et al. Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. J Nucl Med. 2014;55:211\u20135.","journal-title":"J Nucl Med"},{"key":"1743_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s12350-015-0142-3","volume":"23","author":"R Giubbini","year":"2016","unstructured":"Giubbini R, Milan E, Marcassa C, et al. 123I-MIBG thyroid uptake: implications for MIBG imaging of the heart. J Nucl Cardiol. 2016;23:1335\u20139.","journal-title":"J Nucl Cardiol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01743-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T15:29:48Z","timestamp":1653492588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01743-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"11 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}